Kallikrein Cleaves C3 and Activates Complement. 2018

Sarah Irmscher, and Nadia Döring, and Luke D Halder, and Emeraldo A H Jo, and Isabell Kopka, and Christine Dunker, and Ilse D Jacobsen, and Shanshan Luo, and Hortense Slevogt, and Stefan Lorkowski, and Niklas Beyersdorf, and Peter F Zipfel, and Christine Skerka
Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany.

The human plasma contact system is an immune surveillance system activated by the negatively charged surfaces of bacteria and fungi and includes the kallikrein-kinin, the coagulation, and the fibrinolytic systems. Previous work shows that the contact system also activates complement, and that plasma enzymes like kallikrein, plasmin, thrombin, and FXII are involved in the activation process. Here, we show for the first time that kallikrein cleaves the central complement component C3 directly to yield active components C3b and C3a. The cleavage site within C3 is identical to that recognized by the C3 convertase. Also, kallikrein-generated C3b forms C3 convertases, which trigger the C3 amplification loop. Since kallikrein also cleaves factor B to yield Bb and Ba, kallikrein alone can trigger complement activation. Kallikrein-generated C3 convertases are inhibited by factor H; thus, the kallikrein activation pathway merges with the amplification loop of the alternative pathway. Taken together, these data suggest that activation of the contact system locally enhances complement activation on cell surfaces. The human pathogenic microbe Candida albicans activates the contact system in normal human serum. However, C. albicans immediately recruits factor H to the surface, thereby evading the alternative and likely kallikrein-mediated complement pathways.

UI MeSH Term Description Entries
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011415 Complement Factor B A glycine-rich, heat-labile serum glycoprotein that contains a component of the C3 CONVERTASE ALTERNATE PATHWAY (C3bBb). Bb, a serine protease, is generated when factor B is cleaved by COMPLEMENT FACTOR D into Ba and Bb. C3 Proactivator,C3PA,Complement 3 Proactivator,Factor B,Properdin Factor B,Bb Fragment of Factor B,Complement Factor B Fragment, Bb,Complement Factor B, Alternative Pathway,Complement Factor B-Derived Fragment Bb,Complement Factor Ba,Complement Factor Bb,Complement Protein B,Complement Protein Factor B,Properdin Factor Ba,Properdin Factor Bb,Properdin Factor Bf,Properdin Factor Bf F1,Bb, Complement Factor,Complement Factor B Derived Fragment Bb,Factor B, Complement,Factor B, Properdin,Factor Ba, Complement,Factor Ba, Properdin,Factor Bb, Complement,Factor Bb, Properdin,Factor Bf, Properdin,Proactivator, C3,Proactivator, Complement 3,Protein B, Complement
D011416 Complement Factor D A serum protein which is important in the ALTERNATIVE COMPLEMENT ACTIVATION PATHWAY. This enzyme cleaves the COMPLEMENT C3B-bound COMPLEMENT FACTOR B to form C3bBb which is ALTERNATIVE PATHWAY C3 CONVERTASE. Adipsin,C3 Convertase Activator,C3PA Convertase,Factor D,Properdin Factor D,28 kDa Protein, Adipocyte,C3 Proactivator Convertase,C3PAse,Complement Protein D,D Component of Complement,GBGase,Proactivator Convertase,Activator, C3 Convertase,Complement D Component,Convertase Activator, C3,Convertase, C3 Proactivator,Convertase, C3PA,Convertase, Proactivator,Factor D, Complement,Factor D, Properdin,Protein D, Complement
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D002177 Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) Candida Infection,Moniliasis,Candida Infections,Candidiases,Infection, Candida,Moniliases
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003170 Complement Pathway, Alternative Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Alternative Complement Pathway,Properdin Pathway,Alternative Complement Activation Pathway,Complement Activation Pathway, Alternative

Related Publications

Sarah Irmscher, and Nadia Döring, and Luke D Halder, and Emeraldo A H Jo, and Isabell Kopka, and Christine Dunker, and Ilse D Jacobsen, and Shanshan Luo, and Hortense Slevogt, and Stefan Lorkowski, and Niklas Beyersdorf, and Peter F Zipfel, and Christine Skerka
June 2011, Journal of immunology (Baltimore, Md. : 1950),
Sarah Irmscher, and Nadia Döring, and Luke D Halder, and Emeraldo A H Jo, and Isabell Kopka, and Christine Dunker, and Ilse D Jacobsen, and Shanshan Luo, and Hortense Slevogt, and Stefan Lorkowski, and Niklas Beyersdorf, and Peter F Zipfel, and Christine Skerka
September 2014, Science (New York, N.Y.),
Sarah Irmscher, and Nadia Döring, and Luke D Halder, and Emeraldo A H Jo, and Isabell Kopka, and Christine Dunker, and Ilse D Jacobsen, and Shanshan Luo, and Hortense Slevogt, and Stefan Lorkowski, and Niklas Beyersdorf, and Peter F Zipfel, and Christine Skerka
January 2014, Proceedings of the National Academy of Sciences of the United States of America,
Sarah Irmscher, and Nadia Döring, and Luke D Halder, and Emeraldo A H Jo, and Isabell Kopka, and Christine Dunker, and Ilse D Jacobsen, and Shanshan Luo, and Hortense Slevogt, and Stefan Lorkowski, and Niklas Beyersdorf, and Peter F Zipfel, and Christine Skerka
September 1981, Journal of immunology (Baltimore, Md. : 1950),
Sarah Irmscher, and Nadia Döring, and Luke D Halder, and Emeraldo A H Jo, and Isabell Kopka, and Christine Dunker, and Ilse D Jacobsen, and Shanshan Luo, and Hortense Slevogt, and Stefan Lorkowski, and Niklas Beyersdorf, and Peter F Zipfel, and Christine Skerka
January 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
Sarah Irmscher, and Nadia Döring, and Luke D Halder, and Emeraldo A H Jo, and Isabell Kopka, and Christine Dunker, and Ilse D Jacobsen, and Shanshan Luo, and Hortense Slevogt, and Stefan Lorkowski, and Niklas Beyersdorf, and Peter F Zipfel, and Christine Skerka
January 2020, Journal of experimental & clinical cancer research : CR,
Sarah Irmscher, and Nadia Döring, and Luke D Halder, and Emeraldo A H Jo, and Isabell Kopka, and Christine Dunker, and Ilse D Jacobsen, and Shanshan Luo, and Hortense Slevogt, and Stefan Lorkowski, and Niklas Beyersdorf, and Peter F Zipfel, and Christine Skerka
September 2009, The Journal of biological chemistry,
Sarah Irmscher, and Nadia Döring, and Luke D Halder, and Emeraldo A H Jo, and Isabell Kopka, and Christine Dunker, and Ilse D Jacobsen, and Shanshan Luo, and Hortense Slevogt, and Stefan Lorkowski, and Niklas Beyersdorf, and Peter F Zipfel, and Christine Skerka
May 2006, The Journal of clinical investigation,
Sarah Irmscher, and Nadia Döring, and Luke D Halder, and Emeraldo A H Jo, and Isabell Kopka, and Christine Dunker, and Ilse D Jacobsen, and Shanshan Luo, and Hortense Slevogt, and Stefan Lorkowski, and Niklas Beyersdorf, and Peter F Zipfel, and Christine Skerka
May 2021, Microorganisms,
Sarah Irmscher, and Nadia Döring, and Luke D Halder, and Emeraldo A H Jo, and Isabell Kopka, and Christine Dunker, and Ilse D Jacobsen, and Shanshan Luo, and Hortense Slevogt, and Stefan Lorkowski, and Niklas Beyersdorf, and Peter F Zipfel, and Christine Skerka
January 2022, Frontiers in immunology,
Copied contents to your clipboard!